Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

• DOI: 10.1007/s12325-022-02098-1
• Publication Date: 2022-03-14T10:03:01Z
• Authors: Andrew Menzies-Gow; Flavia L. Hoyte; David B. Price; David Cohen; Peter Barker; James Kreindler; Maria Jison; Christopher L. Br...; Peggy Papeleu; Rohit Katial
• Keywords: Benralizumab; Post-hoc analysis; Post hoc

Consensus definitions for clinical remission and super-response were recently established severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody severe, uncontrolled asthma; efficacy safety demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite definition to characterize individual responses benralizumab after 6 12 months. In studies, eligible patients those with asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β2-agonists. post hoc included randomized the approved dose not oral (OCS) at baseline (SIROCCO/CALIMA) OCS ≤ 12.5 mg per day (ZONDA). Individual components zero exacerbations; use; Asthma Control Questionnaire-6 (ACQ-6) score < 1.5 0.75; pre-bronchodilator forced expiratory volume 1 s (FEV1) increase ≥ 100 mL; incorporated exacerbations, use, ACQ-6 0.75, FEV1 mL Overall, 609 (N = 301 N 308) 586 293 293) SIROCCO CALIMA months, respectively; 40 ZONDA SIROCCO/CALIMA, similar 6-month findings, approx. 83% 49% benralizumab, 77% 37% on placebo achieved 2 months; 14.5% (85/586) 7.7% (48/620) Among patients, 75% 48% 35% 20% 22.5% (9/40) 7.5% remission. demonstrates achievable by targeting underlying drivers of inflammation. Precision medicines can help shift treatment paradigms toward treat-to-target, as ultimate therapeutic goal (NCT01928771); (NCT01914757); (NCT02075255). Widely accepted disease are already rheumatoid arthritis, ulcerative colitis, cancer, among others. Two separate expert groups collaborated discuss remission/super-response Both developed separate, yet ways determine whether patient should be considered "in remission." this study, we used results from three ZONDA) that conducted assess therapy called identify who met some all criteria These steroid control score; improvement lung function. Across trials, about quarters two more half months treatment; furthermore, these rates generally numbers treatment. 15–23% approximately 15% within The show biologic therapies like improve symptoms allow achieve